SAN
DIEGO, Aug. 31, 2023 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will be presenting two poster presentations at the 2023
Myotonic Dystrophy Foundation Annual Conference, being held
September 7-9, 2023, in Washington, D.C.
POSTER PRESENTATIONS
September 9, 2023: 12:30 p.m. – 1:30 p.m.
EDT
- From Myotube to Patient: AOC 1001 Demonstrates DMPK
Reduction and Spliceopathy Improvement in a Phase 1/2 Study in
Myotonic Dystrophy Type 1 (DM1) (MARINATM)
- Topline Data Analysis of the Phase 1/2 Clinical Trial
Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type
1: MARINATM
Once available, the posters will be accessible on the
publications page of Avidity's website
at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information
about our AOC platform, clinical development pipeline and people,
please visit www.aviditybiosciences.com and engage with
us on LinkedIn and Twitter.
Investor Contact:
Mike
MacLean
(858) 401-7900
investors@aviditybio.com
Media Contact:
Navjot
Rai
(858) 401-7900
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-2023-myotonic-dystrophy-foundation-annual-conference-301911676.html
SOURCE Avidity Biosciences, Inc.